Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5062 Study Group. Comi G, et al. Among authors: abramsky o. Lancet. 2008 Jun 21;371(9630):2085-92. doi: 10.1016/S0140-6736(08)60918-6. Lancet. 2008. PMID: 18572078 Clinical Trial.
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study.
Comi G, Abramsky O, Arbizu T, Boyko A, Gold R, Havrdová E, Komoly S, Selmaj K, Sharrack B, Filippi M; LAQ/5063 Study Group. Comi G, et al. Among authors: abramsky o. Mult Scler. 2010 Nov;16(11):1360-6. doi: 10.1177/1352458510378127. Epub 2010 Sep 8. Mult Scler. 2010. PMID: 20834039 Clinical Trial.
Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
Freedman MS, Francis GS, Sanders EA, Rice GP, O'Connor P, Comi G, Duquette P, Metz L, Murray TJ, Bouchard JP, Abramsky O, Pelletier J, O'Brien F; Once Weekly Interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS/MRI Research Group. Freedman MS, et al. Among authors: abramsky o, o brien f, o connor p. Mult Scler. 2005 Feb;11(1):41-5. doi: 10.1191/1352458505ms1126oa. Mult Scler. 2005. PMID: 15732265 Clinical Trial.
T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.
Karussis D, Shor H, Yachnin J, Lanxner N, Amiel M, Baruch K, Keren-Zur Y, Haviv O, Filippi M, Petrou P, Hajag S, Vourka-Karussis U, Vaknin-Dembinsky A, Khoury S, Abramsky O, Atlan H, Cohen IR, Abulafia-Lapid R. Karussis D, et al. Among authors: abramsky o. PLoS One. 2012;7(12):e50478. doi: 10.1371/journal.pone.0050478. Epub 2012 Dec 14. PLoS One. 2012. PMID: 23272061 Free PMC article. Clinical Trial.
Neuroprotection in multiple sclerosis.
Karussis D, Grigoriadis S, Polyzoidou E, Grigoriadis N, Slavin S, Abramsky O. Karussis D, et al. Among authors: abramsky o. Clin Neurol Neurosurg. 2006 Mar;108(3):250-4. doi: 10.1016/j.clineuro.2005.11.007. Epub 2006 Jan 4. Clin Neurol Neurosurg. 2006. PMID: 16413962 Review.
312 results